Key terms
About ITOS
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ITOS news
Mar 21
7:30am ET
Analysts Offer Insights on Healthcare Companies: iTeos Therapeutics (ITOS), Rani Therapeutics Holdings (RANI) and Vor Biopharma (VOR)
Mar 12
5:03pm ET
iTeos Therapeutics management to meet with Piper Sandler
Mar 12
6:40am ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), AnaptysBio (ANAB) and iTeos Therapeutics (ITOS)
Mar 11
12:50am ET
Analysts Are Bullish on These Healthcare Stocks: iTeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)
Mar 07
6:30am ET
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), iTeos Therapeutics (ITOS) and Rezolute (RZLT)
Mar 06
7:05am ET
iTeos Therapeutics reports Q4 EPS (85c), consensus ($1.03)
Mar 06
7:05am ET
iTeos Therapeutics appoints DeSimone to board of directors
Jan 08
7:40am ET
iTeos Therapeutics announces 2024 strategic priorities, anticipated milestones
No recent news articles are available for ITOS
No recent press releases are available for ITOS
ITOS Financials
Key terms
Ad Feedback
ITOS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ITOS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range